Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer

被引:2
作者
Cosso, Federica [1 ]
Lavacchi, Daniele [1 ]
Fancelli, Sara [1 ,2 ]
Caliman, Enrico [1 ,2 ]
Brugia, Marco [3 ]
Rossi, Gemma [1 ]
Winchler, Costanza [1 ]
Pillozzi, Serena [2 ,3 ]
Antonuzzo, Lorenzo [1 ,2 ,3 ]
机构
[1] Careggi Univ Hosp, Clin Oncol Unit, Florence, Italy
[2] Univ Florence, Dept Expt & Clin Med, Florence, Italy
[3] Careggi Univ Hosp, Med Oncol Unit, Florence, Italy
关键词
colorectal cancer; long-responders; multikinase inhibitor; regorafenib; VEGF; BEVACIZUMAB; PROGRESSION;
D O I
10.1097/CAD.0000000000001410
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer (CRC) is the third most common cancer worldwide, with approximately 1.9 million new diagnoses and 935 000 deaths annually. Overall, there is accumulating evidence that receiving all available treatments leads to a survival advantage and, although tailored treatments might be appropriate for selected patients, the one-size-fits-all approach is still widely used in chemo-refractory patients. Currently, different antiangiogenics and multitarget agents are indicated in treatment of metastatic CRC (mCRC) whereas the identification of useful predictive factors for the treatment response is lacking. Analysis of potential predictive biomarkers of efficacy of regorafenib is still ongoing but may prove to be difficult because of its nonspecific activity across a wide range of angiogenic, oncogenic, stromal, and intracellular signaling kinases. We present a case of a 57-year-old Caucasian woman diagnosed with recurrence after curative surgery for rectal adenocarcinoma stage III (ypT3N2). Despite undergoing multiple lines of standard chemotherapy, disease control could not be maintained. Consequently, regorafenib, a multikinase inhibitor with antiangiogenic proprieties, was started as a late-line treatment and a dose reduction strategy allowed a long-term response of more than 9 years with good tolerability.
引用
收藏
页码:451 / 454
页数:4
相关论文
共 35 条
[1]   Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer [J].
Antoniotti, Carlotta ;
Marmorino, Federica ;
Boccaccino, Alessandra ;
Martini, Silvia ;
Antista, Maria ;
Rossini, Daniele ;
Zuco, Valentina ;
Prisciandaro, Michele ;
Conca, Veronica ;
Zucchelli, Gemma ;
Borelli, Beatrice ;
Cosentino, Paola ;
Germani, Marco M. ;
Bosco, Maria F. ;
Carullo, Martina ;
Vetere, Guglielmo ;
Moretto, Roberto ;
Giordano, Mirella ;
Masi, Gianluca ;
Pietrantonio, Filippo ;
Zaffaroni, Nadia ;
Cremolini, Chiara .
EUROPEAN JOURNAL OF CANCER, 2022, 165 :116-124
[2]   Osteonecrosis of the Jaw and Angiogenesis Inhibitors: A Revival of a Rare but Serous Side Effect [J].
Antonuzzo, Lorenzo ;
Lunghi, Alice ;
Petreni, Paolo ;
Brugia, Marco ;
Laffi, Alice ;
Giommoni, Elisa ;
Mela, Marinella M. ;
Mazzoni, Francesca ;
Balestri, Vanni ;
Di Costanzo, Francesco .
CURRENT MEDICINAL CHEMISTRY, 2017, 24 (28) :3068-3076
[3]   Regorafenib Also Can Cause Osteonecrosis of the Jaw [J].
Antonuzzo, Lorenzo ;
Lunghi, Alice ;
Giommoni, Elisa ;
Brugia, Marco ;
Di Costanzo, Francesco .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (04)
[4]   Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study [J].
Antonuzzo, Lorenzo ;
Giommoni, Elisa ;
Pastorelli, Davide ;
Latiano, Tiziana ;
Pavese, Ida ;
Azzarello, Domenico ;
Aieta, Michele ;
Pastina, Ilaria ;
Di Fabio, Francesca ;
Bertolini, Alessandro ;
Corsi, Domenico Cristiano ;
Mogavero, Selene ;
Angelini, Valentina ;
Pazzagli, Mario ;
Di Costanzo, Francesco .
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) :7281-7288
[5]   Changes in colorectal cancer incidence in seven high-income countries: a population-based study [J].
Araghi, Marzieh ;
Soerjomataram, Isabelle ;
Bardot, Aude ;
Ferlay, Jacques ;
Cabasag, Citadel J. ;
Morrison, David S. ;
De, Prithwish ;
Tervonen, Hanna ;
Walsh, Paul M. ;
Bucher, Oliver ;
Engholm, Gerda ;
Jackson, Christopher ;
McClure, Carol ;
Woods, Ryan R. ;
Saint-Jacques, Nathalie ;
Morgan, Eileen ;
Ransom, David ;
Thursfield, Vicky ;
Moller, Bjorn ;
Leonfellner, Suzanne ;
Guren, Marianne G. ;
Bray, Freddie ;
Arnold, Melina .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (07) :511-518
[6]   Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report [J].
Baik, Hyungjoo ;
Lee, Hee Ju ;
Park, Jueun ;
Park, Ha Young ;
Park, Jinyoung ;
Lee, Sunseong ;
Bae, Ki Beom .
MOLECULAR AND CLINICAL ONCOLOGY, 2021, 15 (05)
[7]   Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study [J].
Bekaii-Saab, Tanios S. ;
Ou, Fang-Shu ;
Ahn, Daniel H. ;
Boland, Patrick M. ;
Ciombor, Kristen K. ;
Heying, Erica N. ;
Dockter, Travis J. ;
Jacobs, Nisha L. ;
Pasche, Boris C. ;
Cleary, James M. ;
Meyers, Jeffrey P. ;
Desnoyers, Rodwige J. ;
McCune, Jeannines ;
Pedersen, Katrina ;
Barzi, Afsaneh ;
Chiorean, E. Gabriela ;
Sloan, Jeffrey ;
Lacouture, Mario E. ;
Lenz, Heinz-Josef ;
Grothey, Axel .
LANCET ONCOLOGY, 2019, 20 (08) :1070-1082
[8]  
Benson AB., 2021, J NATL COMPR CANC NE, DOI DOI 10.6004/JNCCN.2021.0012
[9]   TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer [J].
Borelli, Beatrice ;
Moretto, Roberto ;
Lonardi, Sara ;
Bonetti, Andrea ;
Antoniotti, Carlotta ;
Pietrantonio, Filippo ;
Masi, Gianluca ;
Burgio, Valentina ;
Marmorino, Federica ;
Salvatore, Lisa ;
Rossini, Daniele ;
Zaniboni, Alberto ;
Zucchelli, Gemma ;
Martignetti, Angelo ;
Di Battista, Monica ;
Pella, Nicoletta ;
Passardi, Alessandro ;
Boccaccino, Alessandra ;
Leone, Francesco ;
Colombo, Camilla ;
Granetto, Cristina ;
Vannini, Francesca ;
Marsico, Valentina Angela ;
Martinelli, Erika ;
Antonuzzo, Lorenzo ;
Vitello, Stefano ;
Delliponti, Laura ;
Boni, Luca ;
Cremolini, Chiara ;
Falcone, Alfredo .
ESMO OPEN, 2018, 3 (04)
[10]   Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report [J].
Callebout, Eduard ;
Ribeiro, Suzane Moura ;
Laurent, Stephanie ;
De Man, Marc ;
Ferdinande, Liesbeth ;
Claes, Kathleen B. M. ;
Van der Meulen, Joni ;
Geboes, Karen P. .
BMC CANCER, 2019, 19 (1)